Generic Name and Formulations:
Erythromycin (as base) 250mg; e-c pellets in caps.
Mayne Pharma US
Indications for ERYC:
Treatment of susceptible infections including upper and lower respiratory, skin and skin structure, genitourinary, Legionnaires' disease, pertussis, listeriosis. Prophylaxis for rheumatic fever attacks in penicillin-allergic patients.
Give 1hr before meals. Usual dose: 250mg every 6hrs or 500mg every 12hrs; max 4g/day (1g/day for twice daily dosing). Legionnaires: 1–4g/day in divided doses. Prophylaxis: 250mg twice daily. See full labeling.
Give 1hr before meals. Usual dose: 30–50mg/kg/day in divided doses; may double dose in severe infections. See full labeling.
Concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine, statins (eg, lovastatin, simvastatin).
Avoid in proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); risk of QT prolongation. Myasthenia gravis. Hepatic impairment. Elderly. Infants: risk of infantile hypertrophic pyloric stenosis; monitor for vomiting or irritability with feeding. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate theophylline (reduce dose of theophylline), digoxin, oral anticoagulants, hexobarbital, phenytoin, valproate. May potentiate CYP3A substrates (eg, triazolam, midazolam, statins [rhabdomyolysis], sildenafil [reduce dose of sildenafil], colchicine [reduce starting dose of colchicine, max dose should be lowered; monitor], verapamil, amlodipine, diltiazem, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine); consider dose adjustments and monitor. May be antagonized by theophylline. Hypotension, bradyarrhythmias, lactic acidosis with verapamil. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics; avoid. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation, C. difficile-associated diarrhea, superinfection (discontinue if occurs).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics